10-K: Plus Therapeutics Navigates Financial Headwinds, Advances Cancer Therapies

Plus Therapeutics reports significant net losses and going concern doubts for fiscal year 2025, while advancing its CNS cancer radiopharmaceutical and diagnostic pipeline with key clinical milestones and commercial agreements.

Summary

• Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers.
• The CNSide Cerebrospinal Fluid Tumor Cell Enumeration test (CNSide Test) was re-introduced in August 2025 and has secured national agreements with UnitedHealthcare and Humana, expanding access to over 67 million covered lives.
• The lead radiopharmaceutical candidate, rhenium (186Re) obisbemeda, is being developed for recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC).
• Phase 1 of the ReSPECT-GBM trial for recurrent GBM is completed, with full enrollment into Phase 2 targeted by the end of 2026, supported by a $3.0 million NIH/NCI award.
• The ReSPECT-LM Phase 1 single-dose escalation trial for LM was completed on February 26, 2025, identifying a recommended Phase 2 dose of 44.1 mCi, and one patient achieved a complete response.
• A ReSPECT-LM open-label, multi-dose Phase 1/2 trial has been initiated and is currently enrolling patients.
• The FDA granted orphan drug designation for rhenium (186Re) obisbemeda for GBM (September 2020), breast cancer with LM (November 2023), and lung cancer with LM (March 2025).
• The FDA cleared the IND application for the ReSPECT-PBC trial for pediatric brain cancer on June 25, 2025, with Phase 1 enrollment anticipated in 2026, supported by a $3.0 million DoD Award.
• The acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is in preclinical development for solid organ cancers, including liver cancer, and will be regulated as a medical device.
• The company incurred a net loss of $22.4 million for the fiscal year ended December 31, 2025, and had an accumulated deficit of $515.9 million.
• Net cash used in operating activities for FY2025 was $20.8 million.
• As of December 31, 2025, cash, cash equivalents, restricted cash, and short-term investments totaled $13.1 million.
• The company received a notice of non-compliance with the Nasdaq Minimum Bid Requirement in May 2025 and was granted an extension until May 11, 2026, to regain compliance, potentially requiring a reverse stock split.
• A public offering in January 2026 raised approximately $13.3 million in net proceeds, extending the cash runway until approximately 2027.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial report, with significant losses and going concern warnings overshadowing positive clinical progress. While pipeline advancements and recent funding are encouraging, the persistent financial instability and Nasdaq compliance issues indicate high risk.

Positives

• The CNSide Test was re-introduced in August 2025 and secured national agreements with UnitedHealthcare and Humana, expanding access to over 67 million covered lives across the United States.
• The ReSPECT-LM Phase 1 single-dose escalation trial was completed on February 26, 2025, successfully determining a recommended Phase 2 dose of 44.1 mCi, with one patient achieving a complete response (eradication of tumor cells in CSF).
• The ReSPECT-LM open-label, multi-dose Phase 1/2 trial has been initiated and is currently enrolling patients, with initial Cohort 1 delivery showing no dose-limiting toxicity.
• FDA granted orphan drug designation for rhenium (186Re) obisbemeda for GBM (September 2020), breast cancer with LM (November 2023), and lung cancer with LM (March 2025), which may provide market exclusivity and financial incentives.
• The FDA cleared the Investigational New Drug (IND) application for the ReSPECT-PBC trial for pediatric brain cancer on June 25, 2025, with Phase 1 enrollment anticipated in 2026.
• Secured a $3.0 million award from the Department of Defense (DoD Award) to support the planned expansion of the clinical trial for pediatric brain cancer.
• Completed Phase 1 of the ReSPECT-GBM trial and is targeting full enrollment into Phase 2 by the end of 2026, supported by an active $3.0 million award from the U.S. National Institutes of Health/National Cancer Institute.
• A public offering closed on January 15, 2026, raising approximately $13.3 million in net proceeds, which is expected to extend the cash runway until approximately 2027.
• Compliance with the Nasdaq Minimum Stockholders Equity Requirement was confirmed in August 2025, although the company remains under a one-year monitoring period.

Negatives

• Incurred significant net losses of $22.4 million for the year ended December 31, 2025, an increase from $12.978 million in 2024.
• The accumulated deficit reached $515.9 million as of December 31, 2025.
• Net cash used in operating activities increased to $20.8 million for FY2025, up from $10.6 million in FY2024.
• Uncertainties relating to the ability to fund operations raise substantial doubt about the company's ability to continue as a going concern.
• Received notice of non-compliance with the Nasdaq Minimum Bid Requirement ($1.00 per share) in May 2025 and was granted an extension until May 11, 2026, with a potential need for a reverse stock split.
• The FDA conveyed that there are insufficient data to support the use of circulating tumor cells (CTCs) as an intermediate clinical endpoint for accelerated approval in LM, recommending evaluation of endpoints with established clinical benefit like overall survival.
• Research and development expenditures are expected to increase in 2026 due to ongoing clinical trials and manufacturing scale-up.
• General and administrative expenses are expected to increase in 2026 due to the expansion of the CNSide commercial operations team.
• The company has a history of generating losses and negative cash flows from operations since inception.
• Stockholders may experience substantial dilution in the value of their investment if additional shares of capital stock are issued in the future.

Risks

• Incurred losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable; operating results have been and will likely continue to be volatile.
• Uncertainties relating to ability to fund operations raise substantial doubt about ability to continue as a going concern.
• Could be delisted from Nasdaq for failure to comply with the Minimum Stockholders Equity Requirement or the Minimum Bid Requirement or other applicable continued listing requirements and standards of Nasdaq.
• Will need substantial additional funding to develop product candidates and conduct future operations and to repay outstanding debt obligations; inability to obtain funds may lead to delays, scaling back, or elimination of product development activities or inability to continue business operations.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate financial statements on a timely basis.
• Future success is largely dependent upon ability to successfully develop nanomedicine platform and commercialize rhenium (186Re) obisbemeda and 188RNL-BAM; any failure to do so could significantly harm business and prospects.
• Inability to successfully partner with other companies to commercialize product candidates could materially suffer.
• Success depends in substantial part on ability to obtain regulatory approvals for RNL product candidates; no certainty of receiving regulatory approval.
• If any party to a key collaboration, licensing, development, acquisition or similar arrangement fails to perform material obligations, or commits a breach, or any arrangement is terminated, there could be an adverse effect on business.
• Reliance on government funding for programs may impose requirements that limit ability to take certain actions, and subject to potential financial penalties.
• Competitors may market or develop products more effectively, approved more quickly, or demonstrated to be safer or more effective, reducing or eliminating commercial opportunities.
• Product development involves a lengthy and expensive process, with an uncertain outcome; may incur additional costs or experience delays in completing, or ultimately be unable to complete, development and commercialization.
• Clinical trial results may fail to support approval of product candidates.
• If third parties engaged are not able to successfully perform, may not be able to successfully complete clinical development, obtain regulatory approval or commercialize product candidates.
• May have difficulty enrolling, or fail to enroll patients in clinical trials, which could delay or prevent clinical trials.
• If a particular product candidate causes significant adverse events, may be unable to receive regulatory approval or market acceptance.
• If product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, especially by physicians, revenue will be limited.
• All potential applications of product candidates are investigational, which subjects to development and marketing risks.
• Subject to extensive regulation, and requirements to obtain regulatory approvals can be costly, time-consuming, and unpredictable.
• Will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant expense; failure to comply could lead to regulatory agency action.
• Future regulatory processes applicable to Laboratory Developed Tests (LDTs) are uncertain and may prevent obtaining required authorizations or introduce additional costs.
• Adequate coverage and reimbursement from third-party payors may not be available for product candidates, diminishing sales or affecting ability to sell profitably.
• Some in-licensed intellectual property from government-funded programs may be subject to federal regulations (e.g., march-in rights), limiting exclusive rights or ability to contract with non-U.S. manufacturers.
• Orphan drug designation may not ensure market exclusivity.
• Fast Track Designation or Rare Pediatric Disease designation by the FDA may not lead to faster development or regulatory review or approval process.
• If decide to pursue accelerated approval, it may not lead to faster development or regulatory review or approval process and does not increase the likelihood of marketing approval.
• Interruption in supply from a material sole source supplier could harm business.
• May engage in strategic transactions that could impact liquidity, increase expenses, and present significant distractions to management.
• Must maintain quality controls and compliance with manufacturing standards.
• Inability to identify, hire and/or retain key personnel could prevent sustaining or growing business.
• Face potential product liability exposure; if successful claims are brought, may incur substantial liability if insurance coverage is inadequate.
• Failure to adequately protect health information could result in severe harm to reputation and subject to significant liabilities.
• Must comply with environmental laws and regulations, including those pertaining to use of hazardous and biological materials; failure could expose to significant liabilities.
• May not be successful in efforts to develop, fully utilize and monetize the CNSide diagnostic portfolio.
• Clinical laboratories are highly regulated; inability to maintain compliance or changes in regulations could harm financial condition.
• Relationships with customers, healthcare providers, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations; non-compliance could face substantial penalties.
• Diagnostic testing industry is subject to rapid change, which could make current or future products obsolete.
• Success depends in part on ability to protect intellectual property; patent protection is uncertain and trade secrets are difficult to protect.
• May not be able to protect trade secrets.
• May be subject to claims that employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• May incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and may be unable to protect rights.
• If sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome would have a material adverse effect.
• Stockholders may experience substantial dilution in the value of their investment if additional shares of capital stock are issued.
• Market price of common stock may be volatile and fluctuate significantly.
• May be or become the target of securities litigation.
• May issue debt and equity securities or securities convertible into equity securities, any of which may be senior to common stock as to distributions and in liquidation.
• Charter documents contain anti-takeover provisions.
• Presently do not intend to pay cash dividends on common stock.
• If securities and/or industry analysts fail to continue publishing research, change recommendations adversely, or if results do not meet expectations, stock price and trading volume could decline.
• Increased information technology security threats and more sophisticated and targeted computer crime could pose a risk to systems, networks, and products.

Future Outlook

The company expects to continue incurring net losses and negative cash flow from operating activities for at least the next twelve months. Aggregate research and development expenditures are anticipated to increase in 2026 due to ongoing clinical trials (ReSPECT-LM, ReSPECT-PBC) and manufacturing scale-up for rhenium (186Re) obisbemeda. General and administrative expenses are also projected to rise in 2026 with the expansion of the CNSide commercial operations team. The company plans to launch additional CSF tumor characterization tests later in 2026 and is on track for New York state licensure for CNSide in 2027. Enrollment for the Phase 1 ReSPECT-PBC clinical trial is expected to begin in 2026. The recent public offering in January 2026 is expected to extend the cash runway until approximately 2027. The company intends to implement a reverse stock split if necessary to regain Nasdaq Minimum Bid Requirement compliance by May 11, 2026.

Management Comments

• "We believe that we must offer and maintain market competitive compensation and benefit programs for our employees in order to attract and retain qualified personnel."
• "We intend to continue to actively monitor the closing bid price of our common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, we have confirmed to Nasdaq that, if necessary, we will implement a reverse stock split of our outstanding common stock to attempt to regain compliance."
• "We plan to consider the Agency's feedback and propose an updated protocol for our next study for FDA's feedback."
• "We were aligned that CTCs could be considered for use as a secondary endpoint."

Industry Context

StockSavvy.ai notes that Plus Therapeutics operates in the highly competitive and rapidly evolving life science industry, specifically targeting central nervous system (CNS) cancers with radiopharmaceuticals and precision diagnostics. The company's focus on direct localized radiation delivery aims to overcome limitations of traditional external beam radiation therapy, aligning with a broader industry trend towards targeted therapies that minimize damage to healthy tissue. The re-introduction of the CNSide Test and expansion of its platform positions the company within the growing market for advanced cancer diagnostics, particularly for challenging conditions like leptomeningeal metastases. However, the industry faces significant regulatory hurdles, lengthy and expensive development processes, and intense competition from both large pharmaceutical companies and academic institutions, many with greater resources. The ongoing debate and uncertainty surrounding the regulation of Laboratory Developed Tests (LDTs) also represent a key industry-specific challenge for CNSide Diagnostics.

Comparison to Industry Standards

• Rhenium (186Re) obisbemeda radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly used External Beam Radiation Therapy (EBRT), while sparing normal tissue and the brain from radiation exposure.
• Rhenium (186Re) obisbemeda is given during a single, short, in-patient hospital visit, contrasting with EBRT which requires out-patient visits five days a week for approximately four to six weeks.
• The average life expectancy with Glioblastoma (GBM) is less than 24 months, with a one-year survival rate of 40% and a five-year survival rate of around 5%, highlighting the significant unmet medical need that rhenium (186Re) obisbemeda aims to address.
• Leptomeningeal metastases (LM) is highly lethal with an average one-year survival of just 7%, indicating a critical need for more effective treatments like rhenium (186Re) obisbemeda.
• Pediatric high-grade glioma confers a three-year progression-free survival (PFS) of 11-3% and three-year overall survival (OS) of 22-5%, with one-year PFS as low as 40% in recent trials, underscoring the poor prognosis for these patients.
• Ependymomas show a five-year OS of 71-5% for Grade II pathology versus 57-10% for Grade III, and 75-5% for gross total resection versus 54-8% for subtotal resection, demonstrating the severity and difficulty of treatment.
• The FDA has not approved a new therapy for GBM in nearly a decade that has improved overall survival, indicating a persistent unmet medical need that Plus Therapeutics' candidates aim to fill.
• Competitors in recurrent Glioblastoma include EnGeneIC, Berg, Istari, AstraZeneca, Novartis, PharmAbcine, Kairos, Midatech, Oncovir, Infuseon, Astellas, NanoPharmaceuticals, Erasca, OX2, Crimson BioPharm, TMUNITY, Pfizer, Arcus, Photolitec, Samus, DNAtrix, ImmVira, BerGenBio, Boston Scientific, BeiGene, GSK, Bristol Myers Squibb, Eli Lilly, Sumitomo, QED, Chimerix, Accenda, Oblato, VBI, INIGHTEC, Sonalasense, VBL, Medicenna, Mimiva, Gilead, CNS Pharmaceuticals, VAXIMM, Incyte, Celularity, Medicinova, Karyopharm, Nerviano Medical Sciences, Merck, Telix, Neonc, Nuvation Bio, Aadi, ERC, Kazia, Xoft, Basilea, Vigo, Biohaven, Bayer, Kintara, CarThera, and Everfront Biotech.
• Competitors in Leptomeningeal Metastases include Kazia, AstraZeneca, Pfizer, Daiichi-Sankyo, Genentech, Janssen, and NRG Oncology.
• Competitors in Pediatric Brain Cancer include AstraZeneca, Bristol Myers Squibb, Chimerix, Celgene, Eli Lilly, Nektar Therapeutics, Istari Oncology, Novartis, NovoCure, Takeda, Y-mAbs, and Cellectar.
• Competitors in Liver Cancer radioembolization therapy include Boston Scientific, SIR-TEX, and ABK Biomedical.
• Competitors for the CNSide Test include Menarini, Belay Diagnostics, BillionToOne, FYR Diagnostics, Cerevention, Genomic Testing Cooperative, Predicine, Neogenomics, Quest, and LabCorp.

Corporate Governance

Related Party Transactions

• Certain existing accredited investors, including certain directors and executive officers, participated in the May 2024 Private Placement.
• Certain existing accredited investors, including certain existing stockholders, participated in the March 2025 Private Placement.
• The Letter Agreement and Support Letters involved March 2025 Private Placement Purchasers, some of whom are existing stockholders, regarding the return and cancellation of shares and repayment obligations.

Stakeholder Impact

• **Shareholders:** Face potential for substantial dilution from future equity issuances, continued volatility in stock price, and the risk of delisting from Nasdaq due to non-compliance with listing standards. Recent public offerings have already resulted in significant dilution.
• **Employees:** The company aims to offer and maintain market competitive compensation and benefit programs to attract and retain qualified personnel. However, the 'going concern' doubt and need for additional funding could lead to significant reductions in research, development, and administrative operations, including employee base.
• **Patients:** The continued development of novel radiopharmaceuticals and precision diagnostics for severe CNS cancers (GBM, LM, PBC) offers potential for improved treatment options, better quality of life, and extended life expectancy, addressing significant unmet medical needs.
• **Customers (Healthcare Providers/Payors):** The re-introduction of the CNSide Test and securing national agreements with major insurers like UnitedHealthcare and Humana expands access to diagnostic services, potentially benefiting healthcare providers and covered patients.
• **Creditors:** The company has outstanding debt obligations and an ongoing need to raise additional cash to fund operations. The 'going concern' doubt indicates a heightened risk regarding the company's ability to satisfy its financial obligations.

Next Steps

• Target full enrollment into Phase 2 of the ReSPECT-GBM clinical trial by the end of 2026.
• Prepare a clinical study report and manuscript for the ReSPECT-LM Phase 1 trial.
• Consider FDA feedback and propose an updated protocol for the next ReSPECT-LM study.
• Continue enrollment in the ReSPECT-LM Multi-dose Phase 1/2 Study.
• Anticipate beginning enrollment for the Phase 1 ReSPECT-PBC clinical trial in 2026.
• Plan to develop 188RNL-BAM into clinical trials, starting with early preclinical studies to support a future FDA IND submission for liver cancer.
• Launch a portfolio of additional CSF tumor characterization tests that expand the CNSide testing platform later in 2026.
• Contact legacy payors and healthcare providers to support CNSide commercial scale-up in 2026.
• Obtain remaining state licensure for New York for CNSide, on track for 2027.
• Actively monitor common stock bid price and evaluate options, including a reverse stock split, to regain Nasdaq Minimum Bid Requirement compliance by May 11, 2026.
• Seek additional capital from other financing alternatives and sources to ensure adequate funding.
• Continue to maintain compliance with Nasdaq listing standards, especially during the one-year monitoring period for the Minimum Stockholders Equity Requirement until August 22, 2026.

Key Dates

Recommendation

The company faces severe financial distress, including recurring net losses of $22.4 million in FY2025, a substantial accumulated deficit of $515.9 million, and negative cash flow from operations. The explicit 'substantial doubt about its ability to continue as a going concern' is a critical red flag. While clinical programs show some progress and recent capital raises provide a temporary cash runway, the ongoing Nasdaq minimum bid price non-compliance and the continuous need for significant funding indicate a highly precarious financial position. The substantial dilution from recent offerings and the inherent risks of early-stage drug development, coupled with the persistent financial instability, make this a high-risk investment with significant downside potential, warranting a 'sell' recommendation for seasoned investors.

Keywords

Radiopharmaceuticals, CNS cancers, Glioblastoma, Leptomeningeal metastases, Pediatric brain cancer, CNSide Test, Rhenium (186Re) obisbemeda, 188RNL-BAM, Clinical trials, Orphan drug designation, FDA approval, Biotechnology, Medical device, Oncology, Precision diagnostics, Nasdaq compliance, Capital raise, Drug development